

#### **Annual Financial Statements and Other Information**

December 31, 2024

# Invesco V.I. Main Street Small Cap Fund®

2	Schedule	of	Investment	rs

- Financial Statements
- 5 7 Financial Highlights
- 8 Notes to Financial Statements
- 14 Report of Independent Registered Public Accounting Firm
- 15 Tax Information
- 16 Other Information Required in Form N-CSR (Items 8-11)

O-VIMSS-NCSR Invesco Distributors, Inc.

# Schedule of Investments (a)

December 31, 2024

Common Stocks & Other Equity Interests=98.13%   Aerospace & Defense-0.92%   145.657   \$ 8.925.861     Air Freight & Logistics=1.42%   145.657   \$ 8.925.861     Air Freight & Logistics=1.42%   13.760.796     Aluminum-0.81%   192.503   3.507.405     Kaiser Aluminum Corp.   62.054   4.360.534     T.867.939   7.867.939     Application Software=2.67%   167matica, Inc., Class A <sup>(to)</sup>   301.879   7.827.722     MARA Holdings, Inc., Divice   406.660   6.819.688     ServiceTitan, Inc., Divice   433.425   9.739.060     Expression   25.883.126     Asset Management & Custody Banks=1.88%     DigitalBridge Group, Inc., Class B   261.810   10.763.009     Rederated Hermes, Inc., Class B   261.810   10.763.009     Automotive Parts & Equipment=2.48%     Dorman Products, Inc., Divice   114.852   10.189.670     Expression   24.023.796     Automotive Retail=1.75%   24.023.796     Automotive Retail=1.75%   24.023.796     Automotive Retail=1.75%   3.027.276   9.950.237     Biotechnology=5.35%   3.027   15.645.448     Ascendis Pharma A/S, ADR (Denmark)   72.276   9.950.237     BridgeBio Pharma, Inc., Divice   100.115   2.479.83     Biotechnology=5.35%   3.027   3.027.23     BridgeBio Pharma, Inc., Divice   10.0115   2.479.849     Building Products=2.53%   3.057   3.057     Automatical Residential Mortgage Finance=1.57%     PennyMac Financial Services, Inc. (b)   217.727   7.282.968     Construction & Engineering=0.75%     Willison Transmission Holdings, Inc. (c)   217.727   7.282.968     Construction Machinery & Heavy Transportation Equipment=3.25%     Altimor Financial Corp. (c)   217.727   7.282.968     Construction Machinery & Heavy Transportation Equipment=3.25%     Altimor Financial Corp. (c)   227.143   8.899.463     Federal Signal Corp. (c)   80.257   7.414.944     Salado Corp. (c)   3.058, 227.143   8.899.463     Federal Signal Corp. (c)   80.257   7.414.944     Salado Corp. (c)   80.257   7.414.944		Shares	Value
Aerospace & Defense-0.92%           ARR Corp, (INIC)         145,657         \$ 8,925,861           Air Freight & Logistics-1.42%         308,815         13,760,796           Aluminum-0.81%         192,503         3,507,405           Century Aluminum Corp.         62,054         4,360,534           Kaiser Aluminum Corp.         62,054         4,360,534           Informatica, Inc., Class A <sup>(ID)</sup> 301,879         7,827,722           MARA Holdings, Inc., Class A <sup>(ID)</sup> 406,660         6,819,688           ServiceTitan, Inc., Class A <sup>(ID)</sup> 433,425         9,739,060           Vision Software, Inc., Closs B         261,810         10,763,009           Asset Management & Custody Banks-1.88%         BigitalBridge Group, Inc., Class B         261,810         10,763,009           Automotive Parts & Equipment-2.48%         261,810         10,763,009           Pisteen Corp., (Inc., Class B         261,810         10,763,009           Automotive Retail-1.75%         24,023,796           Automotive Retail-1.75%         24,023,796           Automotive Retail-1.75%         99,669         16,927,783           Biotechnology-5,35%         40M,8 Biologics, Inc., (Inc., Inc., Inc.	Common Stocks & Other Equi	ty Interest	s-98.13%
Air Freight & Logistics-1.42%         308,815         13,760,796           Aluminum-0.81%         308,815         13,760,796           Century Aluminum Corp.         62,054         4,360,534           Kaiser Aluminum Corp.         62,054         4,360,534           Rafor,939         Application Software-2.67%         301,879         7,827,722           MARA Holdings, Inc. (Inc.) (Inc.	Aerospace & Defense-0.92%	•	
Hub Group, Inc., Class Alco   192,503   3,507,405	AAR Corp. (b)(c)	145,657	\$ 8,925,861
Hub Group, Inc., Class Alco   192,503   3,507,405	Air Freight & Logistics-1 42%		
Aluminum-0.81% Century Aluminum Corp. 192,503 3,507,405 Kaiser Aluminum Corp. 62,054 4,360,534 7,867,939  Application Software-2.67% Informatica, Inc., Class A <sup>(ii)</sup> 301,879 7,827,722 MARA Holdings, Inc., ( <sup>(ii)</sup> Ci) 406,660 6,819,688 ServiceTitan, Inc., ( <sup>(ii)</sup> Ci) 14,549 1,496,656 Unity Software, Inc., ( <sup>(ii)</sup> Ci) 433,425 9,739,060 25,883,126  Asset Management & Custody Banks-1.88% DigitalBridge Group, Inc., ( <sup>(ii)</sup> Ci) 658,722 7,430,384 Federated Hermes, Inc., Class B 261,810 10,763,009 18,193,393  Automotive Parts & Equipment-2.48% Dorman Products, Inc., ( <sup>(ii)</sup> Ci) 114,852 10,189,670 24,023,796  Automotive Retail-1.75% Automotive Retail-1.75% Automotive Retail-1.75% Automotive Retail-1.75% Automotive, Inc., ( <sup>(ii)</sup> Ci) 99,669 16,927,783  Biotechnology-5.35% ADMA Biologics, Inc., ( <sup>(ii)</sup> Ci) 175,246 4,808,750 Inmunovant, Inc., ( <sup>(ii)</sup> Ci) 100,115 2,479,849 Merus N.V. ((Netherlands), ( <sup>(ii)</sup> Ci) 100,115 2,479,849 Merus N.V. ((Netherlands), 111,130 4,675,239  Building Products-2.53% Hayward Holdings, Inc., ( <sup>(ii)</sup> Ci) 111,130 4,675,239  Building Products-2.53% Hayward Holdings, Inc., ( <sup>(ii)</sup> Ci) 473,058 7,233,057 Zurn Elkay Water Solutions Corp., ( <sup>(ii)</sup> Ci) 149,108 15,229,891  Comstruction & Engineering-0.75% WillScot Holdings Corp., ( <sup>(ii)</sup> Ci) 217,727 7,282,968  Construction Machinery & Heavy Transportation Equipment-3.25%  Altion Transmission Holdings, Inc. 227,143 8,899,463 Federal Signal Corp., ( <sup>(ii)</sup> Ci) 80,257 7,414,944		308 815	13 760 796
Century Aluminum Corp.         192,503         3,507,405           Kaiser Aluminum Corp.         62,054         4,360,534           7,867,939         7,867,939           Application Software-2.67%           Informatica, Inc., Class A <sup>(b)</sup> 301,879         7,827,722           MARA Holdings, Inc. ( <sup>(b)(c)</sup> 406,660         6,819,688           ServiceTitan, Inc. ( <sup>(b)(c)</sup> 14,549         1,496,656           Unity Software, Inc. ( <sup>(b)(c)</sup> 433,425         9,739,060           Asset Management & Custody Banks-1.88%           DigitalBridge Group, Inc. ( <sup>(c)</sup> )         658,722         7,430,384           Federated Hermes, Inc., Class B         261,810         10,763,009           Automotive Parts & Equipment-2.48%           Dorman Products, Inc. ( <sup>(b)</sup> )         106,786         13,834,126           Visteon Corp. ( <sup>(b)</sup> )         114,852         10,189,670           Automotive Retail-1.75%           AutoNation, Inc. ( <sup>(b)(c)</sup> )         99,669         16,927,783           Biotechnology-5.35%           ADMA Biologics, Inc. ( <sup>(b)</sup> )         912,271         15,645,448           Ascendis Pharma Als, ABR (Denmark) ( <sup>(b)</sup> )         72,276         9,950,237           BridgeBio Pharma, Inc. ( <sup>(b)(c)</sup> )<	·	300,013	15,100,170
Raiser Aluminum Corp.   62,054   4,360,534   7,867,939			
Application Software-2.67%  Informatica, Inc., Class A <sup>(b)</sup> 301,879 7,827,722  MARA Holdings, Inc., Class A <sup>(b)</sup> 406,660 6,819,688 ServiceTitan, Inc., Cloc 14,549 1,496,656  Unity Software, Inc., Cloc 433,425 9,739,060			
Application Software-2.67% Informatica, Inc., Class A <sup>(b)</sup> 301,879 7,827,722  MARA Holdings, Inc., Divic) 406,660 6,819,688 ServiceTitan, Inc., Divic) 14,549 1,496,656 Unity Software, Inc., Divic) 433,425 9,739,060	Kaiser Aluminum Corp.	62,054	
Informatica, Inc., Class A <sup>(b)</sup> 301,879         7,827,722           MARA Holdings, Inc., (Di(c)         406,660         6,819,688           Service Titan, Inc., (Di(c)         14,549         1,496,656           Unity Software, Inc., (Di(c)         433,425         9,739,060           Experiment & Custody Banks-1.88%           DigitalBridge Group, Inc., (c)         658,722         7,430,384           Federated Hermes, Inc., Class B         261,810         10,763,009           Automotive Parts & Equipment-2.48%         106,786         13,834,126           Visteon Corp., (b)         106,786         13,834,126           Visteon Corp., (b)         114,852         10,189,670           Automotive Retail-1.75%           Automotive Retail-1.75%         99,669         16,927,783           Biotechnology-5.35%           ADMA Biologics, Inc., (b)         912,271         15,645,448           Ascendis Pharma A, S., ADR (Denmark), Di         72,276         9,950,237           BridgeBio Pharma, Inc., (b)(c)         100,115         2,479,849           Merus N.V. (Netherlands), Di         57,610         2,422,500           Twist Bioscience Corp., (b)(c)         255,459         11,871,180           Ultragenyx Pharmaceutical, Inc., (b)			7,867,939
MARA Holdings, Inc. (b)(c)	Application Software-2.67%		
ServiceTitan, Inc. (b)(c)	Informatica, Inc., Class A <sup>(b)</sup>	301,879	7,827,722
Unity Software, Inc. (b)(c)	MARA Holdings, Inc. (b)(c)	406,660	6,819,688
Asset Management & Custody Banks-1.88%  DigitalBridge Group, Inc. (c) 658,722 7,430,384 Federated Hermes, Inc., Class B 261,810 10,763,009 18,193,393  Automotive Parts & Equipment-2.48%  Dorman Products, Inc. (b) 106,786 13,834,126 Visteon Corp. (b) 114,852 10,189,670 24,023,796  Automotive Retail-1.75%  Automotive Retail-1.75%  Automotive Retail-1.75%  Abutomotive Retail-1.75%  Abutomotive Retail-1.75%  Abutomotive Retail-1.75%  Abutomotive Retail-1.75%  Abutomotive Retail-1.75%  Application of the part		14,549	1,496,656
Asset Management & Custody Banks-1.88%  DigitalBridge Group, Inc. (c) 658,722 7,430,384 Federated Hermes, Inc., Class B 261,810 10,763,009 18,193,393  Automotive Parts & Equipment-2.48%  Dorman Products, Inc. (b) 106,786 13,834,126 Visteon Corp. (b) 114,852 10,189,670 24,023,796  Automotive Retail-1.75%  AutoMation, Inc. (b)(c) 99,669 16,927,783  Biotechnology-5.35%  ADMA Biologics, Inc. (b) 912,271 15,645,448 Ascendis Pharma A/S, ADR (Denmark) 72,276 9,950,237 BridgeBio Pharma, Inc. (b)(c) 175,246 4,808,750 Immunovant, Inc. (b)(c) 100,115 2,479,849 Merus N.V. (Netherlands) 57,610 2,422,500 Twist Bioscience Corp. (b)(c) 255,459 11,871,180 Ultragenyx Pharmaceutical, Inc. (b) 111,130 4,675,239  Building Products-2.53%  Hayward Holdings, Inc. (b) 473,058 7,233,057 Zurn Elkay Water Solutions Corp. (c) 463,216 17,277,957 24,511,014  Commercial & Residential Mortgage Finance-1.57%  PennyMac Financial Services, Inc. (c) 149,108 15,229,891  Construction & Engineering-0.75%  WillScot Holdings Corp. (b)(c) 217,727 7,282,968  Allison Transmission Holdings, Inc. 140,743 15,208,689  Allison Transmission Holdings, Inc. 140,743 8,899,463  Federal Signal Corp. (c) 80,257 7,414,944	Unity Software, Inc. (b)(c)	433,425	9,739,060
DigitalBridge Group, Inc. (C)         658,722         7,430,384           Federated Hermes, Inc., Class B         261,810         10,763,009           Automotive Parts & Equipment-2.48%         106,786         13,834,126           Visteon Corp. (b)         114,852         10,189,670           Automotive Retail-1.75%         24,023,796           Automotive Retail-1.75%         4,023,796           Biotechnology-5.35%         99,669         16,927,783           Biotechnology-5.35%         912,271         15,645,448           Ascendis Pharma A/S, ADR (Denmark)(b)         72,276         9,950,237           BridgeBio Pharma, Inc. (b)(c)         175,246         4,808,750           Immunovant, Inc. (b)(c)         100,115         2,479,849           Merus N.V. (Netherlands)(b)         57,610         2,422,500           Twist Bioscience Corp. (b)(c)         255,459         11,871,180           Ultragenyx Pharmaceutical, Inc. (b)         111,130         4,675,239           Building Products-2.53%         43,058         7,233,057           Zurn Elkay Water Solutions Corp. (c)         463,216         17,277,957           Zenny Elkay Water Solutions Corp. (c)         149,108         15,229,891           Construction & Engineering-0.75%           Wi			25,883,126
DigitalBridge Group, Inc. (C)         658,722         7,430,384           Federated Hermes, Inc., Class B         261,810         10,763,009           Automotive Parts & Equipment-2.48%         106,786         13,834,126           Visteon Corp. (b)         114,852         10,189,670           Automotive Retail-1.75%         24,023,796           Automotive Retail-1.75%         4,023,796           Biotechnology-5.35%         99,669         16,927,783           Biotechnology-5.35%         912,271         15,645,448           Ascendis Pharma A/S, ADR (Denmark)(b)         72,276         9,950,237           BridgeBio Pharma, Inc. (b)(c)         175,246         4,808,750           Immunovant, Inc. (b)(c)         100,115         2,479,849           Merus N.V. (Netherlands)(b)         57,610         2,422,500           Twist Bioscience Corp. (b)(c)         255,459         11,871,180           Ultragenyx Pharmaceutical, Inc. (b)         111,130         4,675,239           Building Products-2.53%         43,058         7,233,057           Zurn Elkay Water Solutions Corp. (c)         463,216         17,277,957           Zenny Elkay Water Solutions Corp. (c)         149,108         15,229,891           Construction & Engineering-0.75%           Wi	Asset Management & Custody B	anks-1 900/	
Automotive Parts & Equipment-2.48%  Dorman Products, Inc. (b) 106,786 13,834,126  Visteon Corp. (b) 114,852 10,189,670 24,023,796  Automotive Retail-1.75%  AutoMation, Inc. (b)(c) 99,669 16,927,783  Biotechnology-5.35%  ADMA Biologics, Inc. (b) 912,271 15,645,448  Ascendis Pharma A/S, ADR (Denmark) 72,276 9,950,237  BridgeBio Pharma, Inc. (b)(c) 100,115 2,479,849  Merus N.V. (Netherlands) 57,610 2,422,500  Twist Bioscience Corp. (b)(c) 255,459 11,871,180  Ultragenyx Pharmaceutical, Inc. (b) 111,130 4,675,239  Building Products-2.53%  Hayward Holdings, Inc. (b) 473,058 7,233,057  Zurn Elkay Water Solutions Corp. (c) 463,216 17,277,957  Zurn Elkay Water Solutions Corp. (c) 149,108 15,229,891  Construction & Engineering-0.75%  WillScot Holdings Corp. (b)(c) 217,727 7,282,968  Construction Machinery & Heavy Transportation Equipment-3.25%  Allison Transmission Holdings, Inc. 140,743 15,208,689  Almus Filtration Technologies, Inc. 227,143 8,899,463  Federal Signal Corp. (c) 80,257 7,414,944			7 120 201
Automotive Parts & Equipment-2.48%  Dorman Products, Inc. (b) 106,786 13,834,126 Visteon Corp. (c) 114,852 10,189,670 24,023,796  Automotive Retail-1.75%  AutoNation, Inc. (b)(c) 99,669 16,927,783  Biotechnology-5.35%  ADMA Biologics, Inc. (b) 912,271 15,645,448 Ascendis Pharma, Inc. (b)(c) 172,276 9,950,237  BridgeBio Pharma, Inc. (b)(c) 100,115 2,479,849  Merus N.V. (Netherlands) 57,610 2,422,500 Twist Bioscience Corp. (b)(c) 255,459 11,871,180  Ultragenyx Pharmaceutical, Inc. (b) 111,130 4,675,239  Building Products-2.53%  Hayward Holdings, Inc. (b) 473,058 7,233,057  Zurn Elkay Water Solutions Corp. (c) 463,216 17,277,957  Construction & Engineering-0.75%  WillScot Holdings Corp. (b)(c) 217,727 7,282,968  Construction Machinery & Heavy Transportation Equipment-3.25%  Allison Transmission Holdings, Inc. 140,743 15,208,689  Almus Filtration Technologies, Inc. 227,143 8,899,463  Federal Signal Corp. (c) 80,257 7,414,944			
Automotive Parts & Equipment-2.48%  Dorman Products, Inc. (b) 106,786 13,834,126 Visteon Corp. (b) 114,852 10,189,670  24,023,796  Automotive Retail-1.75%  AutoNation, Inc. (b)(c) 99,669 16,927,783  Biotechnology-5.35%  ADMA Biologics, Inc. (b) 912,271 15,645,448  Ascendis Pharma A/S, ADR (Denmark) 72,276 9,950,237  BridgeBio Pharma, Inc. (b)(c) 175,246 4,808,750  Immunovant, Inc. (b)(c) 100,115 2,479,849  Merus N.V. (Netherlands)(b) 57,610 2,422,500  Twist Bioscience Corp. (b)(c) 255,459 11,871,180  Ultragenyx Pharmaceutical, Inc. (b) 111,130 4,675,239  Building Products-2.53%  Hayward Holdings, Inc. (b) 473,058 7,233,057  Zurn Elkay Water Solutions Corp. (c) 463,216 17,277,957  Commercial & Residential Mortgage Finance-1.57%  PennyMac Financial Services, Inc. (c) 149,108 15,229,891  Construction & Engineering-0.75%  WillScot Holdings Corp. (b)(c) 217,727 7,282,968  Construction Machinery & Heavy Transportation Equipment-3.25%  Allison Transmission Holdings, Inc. 140,743 15,208,689  Almus Filtration Technologies, Inc. 227,143 8,899,463  Federal Signal Corp. (c) 80,257 7,414,944	redefated fierfiles, file., class b	201,010	
Dorman Products, Inc. (b)   106,786   13,834,126     Visteon Corp. (b)   114,852   10,189,670			10,173,373
National Corp.   Nati	Automotive Parts & Equipment-2	2.48%	
Automotive Retail-1.75%  AutoNation, Inc. (b)(c) 99,669 16,927,783  Biotechnology-5.35%  ADMA Biologics, Inc. (b) 912,271 15,645,448  Ascendis Pharma A/S, ADR (Denmark)(b) 72,276 9,950,237  BridgeBio Pharma, Inc. (b)(c) 175,246 4,808,750  Immunovant, Inc. (b)(c) 100,115 2,479,849  Merus N.V. (Netherlands)(b) 57,610 2,422,500  Twist Bioscience Corp. (b)(c) 255,459 11,871,180  Ultragenyx Pharmaceutical, Inc. (b) 111,130 4,675,239  Building Products-2.53%  Hayward Holdings, Inc. (b) 473,058 7,233,057  Zurn Elkay Water Solutions Corp. (c) 463,216 17,277,957  Zung Elkay Water Solutions Corp. (c) 149,108 15,229,891  Construction & Engineering-0.75%  WillScot Holdings Corp. (b)(c) 217,727 7,282,968  Construction Machinery & Heavy Transportation Equipment-3,25%  Allison Transmission Holdings, Inc. 140,743 15,208,689  Atmus Filtration Technologies, Inc. 227,143 8,899,463  Federal Signal Corp. (c) 80,257 7,414,944		106,786	13,834,126
Automotive Retail-1.75%  AutoNation, Inc. (b)(c) 99,669 16,927,783  Biotechnology-5.35%  ADMA Biologics, Inc. (b) 912,271 15,645,448  Ascendis Pharma A/S, ADR (Denmark) 72,276 9,950,237  BridgeBio Pharma, Inc. (b)(c) 175,246 4,808,750  Immunovant, Inc. (b)(c) 100,115 2,479,849  Merus N.V. (Netherlands)(b) 57,610 2,422,500  Twist Bioscience Corp. (b)(c) 255,459 11,871,180  Ultragenyx Pharmaceutical, Inc. (b) 111,130 4,675,239  Building Products-2.53%  Hayward Holdings, Inc. (b) 473,058 7,233,057  Zurn Elkay Water Solutions Corp. (c) 463,216 17,277,957  Zurn Elkay Water Solutions Corp. (c) 149,108 15,229,891  Construction & Engineering-0.75%  WillScot Holdings Corp. (b)(c) 217,727 7,282,968  Construction Machinery & Heavy Transportation Equipment-3,25%  Allison Transmission Holdings, Inc. 140,743 15,208,689  Atmus Filtration Technologies, Inc. 227,143 8,899,463  Federal Signal Corp. (c) 80,257 7,414,944	Visteon Corp. (b)	114,852	10,189,670
AutoNation, Inc. (b)(c)         99,669         16,927,783           Biotechnology-5.35%           ADMA Biologics, Inc. (b)         912,271         15,645,448           Ascendis Pharma A/S, ADR (Denmark) (b)         72,276         9,950,237           BridgeBio Pharma, Inc. (b)(c)         175,246         4,808,750           Immunovant, Inc. (b)(c)         100,115         2,479,849           Merus N.V. (Netherlands)(b)         57,610         2,422,500           Twist Bioscience Corp. (b)(c)         255,459         11,871,180           Ultragenyx Pharmaceutical, Inc. (b)         111,130         4,675,239           Building Products-2.53%           Hayward Holdings, Inc. (b)         473,058         7,233,057           Zurn Elkay Water Solutions Corp. (c)         463,216         17,277,957           Commercial & Residential Mortgage Finance-1.57%           PennyMac Financial Services, Inc. (c)         149,108         15,229,891           Construction & Engineering-0.75%           WillScot Holdings Corp. (b)(c)         217,727         7,282,968           Construction Machinery & Heavy Transportation Equipment-3.25%           Allison Transmission Holdings, Inc.         140,743         15,208,689           Atmus Filtration Technologies, Inc.			24,023,796
AutoNation, Inc. (b)(c)         99,669         16,927,783           Biotechnology-5.35%           ADMA Biologics, Inc. (b)         912,271         15,645,448           Ascendis Pharma A/S, ADR (Denmark) (b)         72,276         9,950,237           BridgeBio Pharma, Inc. (b)(c)         175,246         4,808,750           Immunovant, Inc. (b)(c)         100,115         2,479,849           Merus N.V. (Netherlands)(b)         57,610         2,422,500           Twist Bioscience Corp. (b)(c)         255,459         11,871,180           Ultragenyx Pharmaceutical, Inc. (b)         111,130         4,675,239           Building Products-2.53%           Hayward Holdings, Inc. (b)         473,058         7,233,057           Zurn Elkay Water Solutions Corp. (c)         463,216         17,277,957           Commercial & Residential Mortgage Finance-1.57%           PennyMac Financial Services, Inc. (c)         149,108         15,229,891           Construction & Engineering-0.75%           WillScot Holdings Corp. (b)(c)         217,727         7,282,968           Construction Machinery & Heavy Transportation Equipment-3.25%           Allison Transmission Holdings, Inc.         140,743         15,208,689           Atmus Filtration Technologies, Inc.	Automotivo Potail-1 75%		
Biotechnology-5.35%   ADMA Biologics, Inc. (b)   912,271   15,645,448   Ascendis Pharma A/S, ADR (Denmark) (b)   72,276   9,950,237   BridgeBio Pharma, Inc. (b)(c)   175,246   4,808,750   Immunovant, Inc. (b)(c)   100,115   2,479,849   Merus N.V. (Netherlands) (b)   57,610   2,422,500   Twist Bioscience Corp. (b)(c)   255,459   11,871,180   Ultragenyx Pharmaceutical, Inc. (b)   111,130   4,675,239   51,853,203   Suilding Products-2.53%   473,058   7,233,057   Zurn Elkay Water Solutions Corp. (c)   463,216   17,277,957   24,511,014   Commercial & Residential Mortgage Finance-1.57%   PennyMac Financial Services, Inc. (c)   149,108   15,229,891   Construction & Engineering-0.75%   WillScot Holdings Corp. (b)(c)   217,727   7,282,968   Construction Machinery & Heavy Transportation Equipment-3.25%   Allison Transmission Holdings, Inc.   140,743   15,208,689   Atmus Filtration Technologies, Inc.   227,143   8,899,463   Federal Signal Corp. (c)   80,257   7,414,944   44.		99 669	16 927 783
ADMA Biologics, Inc. (b) 912,271 15,645,448 Ascendis Pharma A/S, ADR (Denmark) 72,276 9,950,237 BridgeBio Pharma, Inc. (b)(c) 175,246 4,808,750 Immunovant, Inc. (b)(c) 100,115 2,479,849 Merus N.V. (Netherlands) 57,610 2,422,500 Twist Bioscience Corp. (b)(c) 255,459 11,871,180 Ultragenyx Pharmaceutical, Inc. (b) 111,130 4,675,239  Building Products-2.53% Hayward Holdings, Inc. (b) 473,058 7,233,057 Zurn Elkay Water Solutions Corp. (c) 463,216 17,277,957 Zurn Elkay Water Solutions Corp. (c) 149,108 15,229,891  Commercial & Residential Mortgage Finance-1.57% PennyMac Financial Services, Inc. (c) 149,108 15,229,891  Construction & Engineering-0.75% WillScot Holdings Corp. (b)(c) 217,727 7,282,968  Construction Machinery & Heavy Transportation Equipment-3.25% Allison Transmission Holdings, Inc. 140,743 15,208,689 Atmus Filtration Technologies, Inc. 227,143 8,899,463 Federal Signal Corp. (c) 80,257 7,414,944	Autonation, me.	77,007	10,721,103
Ascendis Pharma A/S, ADR (Denmark) <sup>(b)</sup> 72,276 9,950,237 BridgeBio Pharma, Inc. (b)(c) 175,246 4,808,750 Immunovant, Inc. (b)(c) 100,115 2,479,849 Merus N.V. (Netherlands) <sup>(b)</sup> 57,610 2,422,500 Twist Bioscience Corp. (b)(c) 255,459 11,871,180 Ultragenyx Pharmaceutical, Inc. (b) 111,130 4,675,239  Building Products-2.53% Hayward Holdings, Inc. (b) 473,058 7,233,057 Zurn Elkay Water Solutions Corp. (c) 463,216 17,277,957 24,511,014  Commercial & Residential Mortgage Finance-1.57% PennyMac Financial Services, Inc. (c) 149,108 15,229,891  Construction & Engineering-0.75% WillScot Holdings Corp. (b)(c) 217,727 7,282,968  Construction Machinery & Heavy Transportation Equipment-3.25%  Allison Transmission Holdings, Inc. 140,743 15,208,689 Atmus Filtration Technologies, Inc. 227,143 8,899,463 Federal Signal Corp. (c) 80,257 7,414,944			
BridgeBio Pharma, Inc. (b)(c)         175,246         4,808,750           Immunovant, Inc. (b)(c)         100,115         2,479,849           Merus N.V. (Netherlands)(b)         57,610         2,422,500           Twist Bioscience Corp. (b)(c)         255,459         11,871,180           Ultragenyx Pharmaceutical, Inc. (b)         111,130         4,675,239           Building Products-2.53%         51,853,203           Building Products-2.53%         473,058         7,233,057           Zurn Elkay Water Solutions Corp. (c)         463,216         17,277,957           Zurn Elkay Water Solutions Corp. (d)         463,216         17,277,957           PennyMac Financial Services, Inc. (c)         149,108         15,229,891           Construction & Engineering-0.75%           WillScot Holdings Corp. (b)(c)         217,727         7,282,968           Construction Machinery & Heavy Transportation Equipment-3.25%           Allison Transmission Holdings, Inc.         140,743         15,208,689           Atmus Filtration Technologies, Inc.         227,143         8,899,463           Federal Signal Corp. (c)         80,257         7,414,944		912,271	
Immunovant, Inc. (b)(c)   100,115   2,479,849			
Merus N.V. (Netherlands) <sup>(b)</sup> 57,610         2,422,500           Twist Bioscience Corp. (b)(c)         255,459         11,871,180           Ultragenyx Pharmaceutical, Inc. (b)         111,130         4,675,239           51,853,203         51,853,203           Building Products-2.53%           Hayward Holdings, Inc. (b)         473,058         7,233,057           Zurn Elkay Water Solutions Corp. (c)         463,216         17,277,957           Commercial & Residential Mortgage Finance-1.57%           PennyMac Financial Services, Inc. (c)         149,108         15,229,891           Construction & Engineering-0.75%           WillScot Holdings Corp. (b)(c)         217,727         7,282,968           Construction Machinery & Heavy Transportation Equipment-3.25%           Allison Transmission Holdings, Inc.         140,743         15,208,689           Atmus Filtration Technologies, Inc.         227,143         8,899,463           Federal Signal Corp. (c)         80,257         7,414,944			
Twist Bioscience Corp. (b)(c)   255,459   11,871,180     Ultragenyx Pharmaceutical, Inc. (b)   111,130   4,675,239			
Ultragenyx Pharmaceutical, Inc. (b)			
### Style="background-color: blue;">   Style="background-color: blue;" Style="background-color			
Building Products-2.53%           Hayward Holdings, Inc. (b)         473,058         7,233,057           Zurn Elkay Water Solutions Corp. (c)         463,216         17,277,957           24,511,014           Commercial & Residential Mortgage Finance-1.57%           PennyMac Financial Services, Inc. (c)         149,108         15,229,891           Construction & Engineering-0.75%           WillScot Holdings Corp. (b)(c)         217,727         7,282,968           Construction Machinery & Heavy Transportation Equipment-3.25%           Allison Transmission Holdings, Inc.         140,743         15,208,689           Atmus Filtration Technologies, Inc.         227,143         8,899,463           Federal Signal Corp. (c)         80,257         7,414,944	Ultragenyx Pharmaceutical, Inc. (b)	111,130	
Hayward Holdings, Inc. (b)         473,058         7,233,057           Zurn Elkay Water Solutions Corp. (c)         463,216         17,277,957           24,511,014           Commercial & Residential Mortgage Finance-1.57%           PennyMac Financial Services, Inc. (c)         149,108         15,229,891           Construction & Engineering-0.75%           WillScot Holdings Corp. (b)(c)         217,727         7,282,968           Construction Machinery & Heavy Transportation Equipment-3.25%           Allison Transmission Holdings, Inc.         140,743         15,208,689           Atmus Filtration Technologies, Inc.         227,143         8,899,463           Federal Signal Corp. (c)         80,257         7,414,944			51,853,203
Hayward Holdings, Inc. (b)         473,058         7,233,057           Zurn Elkay Water Solutions Corp. (c)         463,216         17,277,957           24,511,014           Commercial & Residential Mortgage Finance-1.57%           PennyMac Financial Services, Inc. (c)         149,108         15,229,891           Construction & Engineering-0.75%           WillScot Holdings Corp. (b)(c)         217,727         7,282,968           Construction Machinery & Heavy Transportation Equipment-3.25%           Allison Transmission Holdings, Inc.         140,743         15,208,689           Atmus Filtration Technologies, Inc.         227,143         8,899,463           Federal Signal Corp. (c)         80,257         7,414,944	Building Products-2.53%		
Zurn Elkay Water Solutions Corp. (c)         463,216         17,277,957           24,511,014         24,511,014           Commercial & Residential Mortgage Finance-1.57%           PennyMac Financial Services, Inc. (c)         149,108         15,229,891           Construction & Engineering-0.75%           WillScot Holdings Corp. (b)(c)         217,727         7,282,968           Construction Machinery & Heavy Transportation Equipment-3.25%         4140,743         15,208,689           Allison Transmission Holdings, Inc.         140,743         15,208,689           Atmus Filtration Technologies, Inc.         227,143         8,899,463           Federal Signal Corp. (c)         80,257         7,414,944		473,058	7,233,057
24,511,014           Commercial & Residential Mortgage Finance-1.57%           PennyMac Financial Services, Inc. (c)         149,108         15,229,891           Construction & Engineering-0.75%           WillScot Holdings Corp. (b)(c)         217,727         7,282,968           Construction Machinery & Heavy Transportation Equipment-3.25%           Allison Transmission Holdings, Inc.         140,743         15,208,689           Atmus Filtration Technologies, Inc.         227,143         8,899,463           Federal Signal Corp. (c)         80,257         7,414,944	Zurn Elkay Water Solutions Corp. (c)		
PennyMac Financial Services, Inc. (c)         149,108         15,229,891           Construction & Engineering-0.75%         WillScot Holdings Corp. (b)(c)         217,727         7,282,968           Construction Machinery & Heavy Transportation Equipment-3.25%         Equipment-3.25%           Allison Transmission Holdings, Inc.         140,743         15,208,689           Atmus Filtration Technologies, Inc.         227,143         8,899,463           Federal Signal Corp. (c)         80,257         7,414,944			
PennyMac Financial Services, Inc. (c)         149,108         15,229,891           Construction & Engineering-0.75%         WillScot Holdings Corp. (b)(c)         217,727         7,282,968           Construction Machinery & Heavy Transportation Equipment-3.25%         Equipment-3.25%           Allison Transmission Holdings, Inc.         140,743         15,208,689           Atmus Filtration Technologies, Inc.         227,143         8,899,463           Federal Signal Corp. (c)         80,257         7,414,944			
Construction & Engineering-0.75%           WillScot Holdings Corp. (b)(c)         217,727         7,282,968           Construction Machinery & Heavy Transportation Equipment-3.25%           Allison Transmission Holdings, Inc.         140,743         15,208,689           Atmus Filtration Technologies, Inc.         227,143         8,899,463           Federal Signal Corp. (c)         80,257         7,414,944		-	
WillScot Holdings Corp. (b)(c)         217,727         7,282,968           Construction Machinery & Heavy Transportation Equipment-3.25%           Allison Transmission Holdings, Inc.         140,743         15,208,689           Atmus Filtration Technologies, Inc.         227,143         8,899,463           Federal Signal Corp. (c)         80,257         7,414,944	PennyMac Financial Services, Inc.	149,108	15,229,891
WillScot Holdings Corp. (b)(c)         217,727         7,282,968           Construction Machinery & Heavy Transportation Equipment-3.25%           Allison Transmission Holdings, Inc.         140,743         15,208,689           Atmus Filtration Technologies, Inc.         227,143         8,899,463           Federal Signal Corp. (c)         80,257         7,414,944	Construction & Engineering-0.75	%	
3.25%         Allison Transmission Holdings, Inc.       140,743       15,208,689         Atmus Filtration Technologies, Inc.       227,143       8,899,463         Federal Signal Corp. (c)       80,257       7,414,944			7,282,968
3.25%         Allison Transmission Holdings, Inc.       140,743       15,208,689         Atmus Filtration Technologies, Inc.       227,143       8,899,463         Federal Signal Corp. (c)       80,257       7,414,944		Tuengaran	
Allison Transmission Holdings, Inc.       140,743       15,208,689         Atmus Filtration Technologies, Inc.       227,143       8,899,463         Federal Signal Corp. (c)       80,257       7,414,944		ıransportat	ion Equipment-
Atmus Filtration Technologies, Inc.         227,143         8,899,463           Federal Signal Corp. (c)         80,257         7,414,944		140 743	15 208 689
Federal Signal Corp. (c) 80,257 7,414,944			
31,323,070		,	
			02,020,070

	Shares	Value
Construction Materials-1.77%	000 705	17.1.10.501
Summit Materials, Inc., Class A <sup>(b)</sup>	338,785	\$ 17,142,521
Diversified Banks-0.59%		
Bank of N.T. Butterfield & Son Ltd. (The) (Bermuda)	157,279	5,748,547
	131,219	3,140,341
Diversified REITs-0.71%	210 211	( 05( 020
Essential Properties Realty Trust, Inc. (c)	219,211	6,856,920
Education Services-1.11%		
Stride, Inc. (b)(c)	103,568	10,763,822
Electric Utilities-1.00%		
Portland General Electric Co. (c)	222,851	9,720,761
Electrical Components & Equipme	ent-1.53%	
Atkore, Inc.	105,157	8,775,352
Regal Rexnord Corp. (c)	38,933	6,039,676
		14,815,028
Electronic Components-2.01%		
Belden, Inc. (c)	127,305	14,335,816
Vishay Intertechnology, Inc. (c)	302,913	5,131,346
		19,467,162
Electronic Equipment & Instrume		.=
Itron, Inc. (b)(c)	139,640	15,162,111
<b>Environmental &amp; Facilities Servic</b>		
ABM Industries, Inc.	213,843	10,944,485
Casella Waste Systems, Inc., Class A <sup>(b)(c)</sup>	138,000	14,601,780
		25,546,265
Footwear-1.07%	044040	10 000 007
Steven Madden Ltd. (c)	244,213	10,383,937
Gas Utilities-1.03%		
Chesapeake Utilities Corp.	82,024	9,953,612
Health Care Equipment-2.33%		
Inspire Medical Systems, Inc. (b)(c)	47,803	8,861,720
Integer Holdings Corp. (b)(c) TransMedics Group, Inc. (b)(c)	78,847	10,448,805
Transmedics Group, Ilic.	52,038	3,244,569 22,555,094
		22,333,074
Health Care Facilities-1.42%	01 721	7 5 4 7 0 5 0
Encompass Health Corp. Surgery Partners, Inc. (b)(c)	81,731 291,929	7,547,858 6,180,137
ourgery runtiners, me.	<i>L</i> )1,) <i>L</i> )	13,727,995
Health Care Services-2.12% Addus HomeCare Corp. (b)(c)	53,465	6,701,838
BrightSpring Health Services, Inc. (b)(c)	321,304	5,471,807
Guardant Health, Inc. (b)(c)	272,955	8,338,775
		20,512,420
Homebuilding-1.50%		
KB Home <sup>(c)</sup>	221,550	14,560,266
Hotel & Resort REITs-1.53%		
DiamondRock Hospitality Co.	1,640,894	14,817,273
	_,0,0 / 1	,0,

	Shares		Value		Shares		Value
Human Resource & Employment	t Services-3.2	20%		Regional Banks-(continued)			
Korn Ferry	210,626	\$	14,206,724	OceanFirst Financial Corp.	314,634	\$	5,694,875
Paycor HCM, Inc. (b)(c)	587,357		10,907,219	Pacific Premier Bancorp, Inc.	400,620		9,983,450
Upwork, Inc. (b)(c)	360,450		5,893,358	United Community Banks, Inc. (c)	224,499		7,253,563
- P			31,007,301	Webster Financial Corp.	194,252		10,726,595
			01,001,001	Wintrust Financial Corp.	140,138		17,476,610
Industrial Machinery & Supplies	& Component	ts-4.0	4%	WSFS Financial Corp. (c)	141,081		7,495,634
Enpro, Inc. (c)	80,147		13,821,350	nor or manetal corp.	111,001		88,617,576
ESAB Corp. (c)	132,242		15,861,105				00,011,511
Gates Industrial Corp. PLC <sup>(b)</sup>	459,617		9,454,322	Research & Consulting Services-	0.77%		
			39,136,777	CACI International, Inc., Class A <sup>(b)</sup>	18,460		7,458,94
Industrial REITs-1.26%				Restaurants-1.48%			
Terreno Realty Corp. (c)	207,424		12,267,055	Dutch Bros, Inc., Class A <sup>(b)</sup>	132,851		6,958,73
Terreno hearty corp.	201,121		12,201,000	Texas Roadhouse, Inc.	41,224		7,438,04
Investment Banking & Brokerage	e-1.37%			rexus reduitedse, me.	11,221		14,396,78
BGC Group, Inc., Class A	476,968		4,321,330				14,570,70
Stifel Financial Corp. (c)	84,432		8,956,547	Semiconductor Materials & Equip	ment-0.99%		
			13,277,877	MKS Instruments, Inc.	91,547		9,556,59
IT Consulting & Other Services-	1 03%		_	Semiconductors-4.37%			
ASGN, Inc. (b)(c)	120,284		10,024,469	Allegro MicroSystems, Inc. (b)(c)	411,901		9,004,15
ASON, IIIC.	120,204		10,024,409	Lattice Semiconductor Corp. (b)(c)	147,493		8,355,47
Life Sciences Tools & Services-1	1.61%			MACOM Technology Solutions Holdings,	147,475		0,333,47
BioLife Solutions, Inc. (b)(c)	290,626		7,544,651	Inc. (b)	117,890		15,315,09
Repligen Corp. (b)(c)	55,760		8,026,094	Silicon Laboratories, Inc. (b)(c)	78,148		9,707,54
- 1 - 2 · · · · · · · · · · · · · · · · · ·			15,570,745	omeon Edbordtories, me.	10,110		42,382,26
			20/0:0/::0				72,302,20
Metal, Glass & Plastic Container				Steel-2.30%			
Silgan Holdings, Inc. <sup>(c)</sup>	229,887		11,965,618	ATI, Inc. <sup>(b)</sup>	249,608		13,738,42
0il 9 Coo Deilling 1 220/				Commercial Metals Co. <sup>(c)</sup>	172,217		8,541,96
Oil & Gas Drilling-1.22%	270 440		11 061 400				22,280,38
Helmerich & Payne, Inc.	370,440		11,861,489				
Oil & Gas Exploration & Producti	ion-3.59%			Systems Software-1.89%			
Civitas Resources, Inc. (c)	268,258		12,304,994	GitLab, Inc., Class A <sup>(b)(c)</sup>	174,785		9,849,13
CNX Resources Corp. (b)(c)	257,258		9,433,651	Progress Software Corp. <sup>(c)</sup>	129,944		8,465,85
Northern Oil and Gas, Inc. (c)	352,901		13,113,801				18,314,98
Northern on and ods, me.	332,701		34,852,446				
			34,032,440	Trading Companies & Distributor			0.046.47
Other Specialized REITs-2.79%				Air Lease Corp., Class A <sup>(c)</sup>	187,025		9,016,47
Four Corners Property Trust, Inc. (c)	537,948		14,599,908	Transaction & Payment Processi	ing Services-C	111	%
Outfront Media, Inc.	704,134		12,491,337	Margeta, Inc., Class A <sup>(b)</sup>	1.043.607	,.±	3,955,27
			27,091,245		, ,		3,933,21
			21,071,213	Total Common Stocks & Other Equity (Cost \$706,055,627)	y iliterests		951,414,019
Personal Care Products-1.31%				(6031 \$100,033,021)			751,414,01
BellRing Brands, Inc. <sup>(b)</sup>	168,900		12,724,926	Money Market Funds-1.71%			
DI 1: 1 0.440/			_	Invesco Government & Agency Portfolio,			
Pharmaceuticals-2.14%	100.450		E E 40 E 70	Institutional Class, 4.42% (d)(e)	5,818,076		5,818,07
Collegium Pharmaceutical, Inc. (b)(c)	193,458		5,542,572	Invesco Treasury Portfolio, Institutional			
Intra-Cellular Therapies, Inc. (b)	155,609		12,996,464	Class, 4.38% <sup>(d)(e)</sup>	10,800,832		10,800,83
Structure Therapeutics, Inc., ADR <sup>(b)(c)</sup>	80,512		2,183,485	Total Money Market Funds (Cost \$1	6,618,908)		16,618,90
			20,722,521	TOTAL INVESTMENTS IN SECURITIES			
December 9 Convolter Incomes	1 770/			(excluding investments purchased			
Property & Casualty Insurance-			11 (7/ 501	with cash collateral from			
Definity Financial Corp. (Canada)	287,160		11,676,581	securities on loan)-99.84%			060 022 02
Skyward Specialty Insurance Group, Inc. (b)(c)	100 E00		E E20 002	(Cost \$722,674,535)			968,032,92
IIIC. VVV	109,598		5,539,083	Investments Purchased with	Cash Collate	ral f	rom
			17,215,664	Securities on Loan		•	- •
Regional Banks-9.14%				Money Market Funds-28.56%			
Berkshire Hills Bancorp, Inc.	206,866		5,881,200	Invesco Private Government Fund.			
Cathay General Bancorp	269,429		12,827,515	4.50% <sup>(d)(e)(f)</sup>	76,835,293		76,835,29
Columbia Banking System, Inc. (c)	417,554		11,278,134				

	Shares		Value
Money Market Funds-(conti	nued)		
Invesco Private Prime Fund, 4.53% <sup>(d)(e)(f)</sup>	199,993,569	\$	200,053,567
Total Investments Purchased from Securities on Loan (C		276,888,860	
TOTAL INVESTMENTS IN SECURITIES (Cost \$999,563,395)	1	1,244,921,787	
OTHER ASSETS LESS LIABILITIES-(2	8.40)%		(275,354,339)
NET ASSETS-100.00%		\$	969,567,448

Investment Abbreviations:

ADR - American Depositary Receipt

REIT - Real Estate Investment Trust

Notes to Schedule of Investments:

- (a) Industry and/or sector classifications used in this report are generally according to the Global Industry Classification Standard, which was developed by and is the exclusive property and a service mark of MSCI Inc. and Standard & Poor's.
- (b) Non-income producing security.

(c) All or a portion of this security was out on loan at December 31, 2024.

Affiliated holding. Affiliated holdings are investments in entities which are under common ownership or control of Invesco Ltd. or are investments in entities in which the Fund owns 5% or more of the outstanding voting securities. The table below shows the Fund's transactions in, and earnings from, its investments in affiliates for the fiscal year ended December 31, 2024.

	Dece	Value mber 31, 2023		Purchases at Cost		Proceeds from Sales	Un: App	ange in realized reciation reciation)	Realiz Gair (Los	n	Dece	Value mber 31, 2024	Divi	dend Income
Investments in Affiliated Money Market Funds:														
Invesco Government & Agency Portfolio, Institutional Class	\$	3,294,388	\$	73,791,205	\$	(71,267,517)	\$	-	\$	-	\$	5,818,076	\$	284,107
Invesco Liquid Assets Portfolio, Institutional Class		2,350,526		26,772,693		(29,121,660)		(537)	(1,0	22)		-		103,941
Invesco Treasury Portfolio, Institutional Class		3,765,014		115,047,909		(108,012,091)		-		-		10,800,832		422,862
Investments Purchased with Cash Collateral from Securities on Loan:														
Invesco Private Government Fund		39,245,776		360,139,390		(322,549,873)		-		-		76,835,293	2	,326,219*
Invesco Private Prime Fund	1	.00,917,711		805,261,612		(706,093,505)	(3	39,833)	7,5	82	2	.00,053,567	6	,262,736*
Total	\$1	.49,573,415	\$1	.,381,012,809	\$(	1,237,044,646)	\$(4	10,370)	\$ 6,5	60	\$2	93,507,768	\$	9,399,865

<sup>\*</sup> Represents the income earned on the investment of cash collateral, which is included in securities lending income on the Statement of Operations. Does not include rebates and fees paid to lending agent or premiums received from borrowers, if any.

<sup>(</sup>e) The rate shown is the 7-day SEC standardized yield as of December 31, 2024.

<sup>(</sup>f) The security has been segregated to satisfy the commitment to return the cash collateral received in securities lending transactions upon the borrower's return of the securities loaned. See Note 1J.

## Statement of Assets and Liabilities

December 31, 2024

#### Assets:

Shares outstanding, no par value, with an unlir shares authorized:		
Series II	\$	756,413,594
Net Assets: Series I	\$	213,153,854
	\$	969,567,448
Distributable earnings		355,840,637
Net assets consist of: Shares of beneficial interest	\$	
Net assets applicable to shares outstanding	\$	969,567,448
Total liabilities		278,663,248
Trustee deferred compensation and retirement plans		79,366
Accrued other operating expenses		39,847
Accrued fees to affiliates		573,870
Collateral upon return of securities loaned		276,888,860
Fund shares reacquired		418,359
Investments purchased		662,946
<b>Liabilities:</b> Payable for:		
Total assets	1	1,248,230,696
Other assets		2,233
Investment for trustee deferred compensation and retirement plans		79,366
Dividends		1,644,689
Receivable for: Fund shares sold		435,459
Foreign currencies, at value (Cost \$27,242)		27,310
Cash		1,119,852
Investments in affiliated money market funds, at value (Cost \$293,507,768)		293,507,768
Investments in unaffiliated securities, at value (Cost \$706,055,627)*	Ś	951,414,019

Series I	7,287,203
Series II	26,547,871
Series I: Net asset value per share	\$ 29.25
Series II: Net asset value per share	\$ 28.49

<sup>\*</sup> At December 31, 2024, securities with an aggregate value of \$267,652,928 were on loan to brokers.

## **Statement of Operations**

For the year ended December 31, 2024

#### Investment income:

investment income:	
Dividends (net of foreign withholding taxes of \$18,813)	\$ 11,858,803
Dividends from affiliated money market funds (includes	
net securities lending income of \$250,221)	1,061,131
Total investment income	12,919,934
Expenses:	
Advisory fees	6,134,904
Administrative services fees	1,485,259
Custodian fees	8,373
Distribution fees - Series II	1,772,835
Transfer agent fees	43,623
Trustees' and officers' fees and benefits	29,853
Reports to shareholders	122,323
Professional services fees	52,021
Other	9,338
Total expenses	9,658,529
Less: Fees waived	(16,970)
Net expenses	9,641,559
Net investment income	3,278,375
Realized and unrealized gain (loss) from:	
Net realized gain from:	
Unaffiliated investment securities	112,180,971
Affiliated investment securities	6,560
Foreign currencies	84
	112,187,615
Change in net unrealized appreciation (depreciation) of:	
Unaffiliated investment securities	(10,372,004)
Affiliated investment securities	(40,370)
Foreign currencies	153
	(10,412,221)
Net realized and unrealized gain	101,775,394
Net increase in net assets resulting from operations	\$105,053,769

# **Statement of Changes in Net Assets**For the years ended December 31, 2024 and 2023

	2024	2023
Operations:		
Net investment income	\$ 3,278,375	\$ 1,835,030
Net realized gain	112,187,615	62,032,381
Change in net unrealized appreciation (depreciation)	(10,412,221)	63,246,989
Net increase in net assets resulting from operations	105,053,769	127,114,400
Distributions to shareholders from distributable earnings:		
Series I	(7,337,261)	(1,849,665)
Series II	(27,012,158)	(5,700,796)
Total distributions from distributable earnings	(34,349,419)	(7,550,461)
Share transactions-net:		
Series I	23,344,941	6,807,397
Series II	35,263,594	8,425,063
Net increase in net assets resulting from share transactions	58,608,535	15,232,460
Net increase in net assets	129,312,885	134,796,399
Net assets:		
Beginning of year	840,254,563	705,458,164
End of year	\$969,567,448	\$840,254,563

## Financial Highlights

The following schedule presents financial highlights for a share of the Fund outstanding throughout the periods indicated.

	Net asset value , beginning of period	Net investment income (loss) <sup>(a)</sup>	Net gains (losses) on securities (both realized and unrealized)	Total from investment operations	Dividends from net investment income	Distributions from net realized gains	Total distributions	Net asset value, end of period	Total return <sup>(b)</sup>	Net assets , end of period (000's omitted)	Ratio of expenses to average net assets with fee waivers and/or expenses absorbed	Ratio of expenses to average net assets without fee waivers and/or expenses absorbed	Ratio of net investment income (loss) to average net assets	Portfolio turnover <sup>(c)</sup>
Series I								·						
Year ended 12/31/24	\$26.91	\$ 0.16	\$ 3.24	\$ 3.40	\$ -	\$(1.06)	\$(1.06)	\$29.25	12.69%	\$213,154	0.87%	0.87%	0.56%	42%
Year ended 12/31/23	23.08	0.11	4.01	4.12	(0.29)	-	(0.29)	26.91	18.13	174,202	0.88	0.88	0.44	42
Year ended 12/31/22	31.47	0.11	(5.12)	(5.01)	(0.15)	(3.23)	(3.38)	23.08	(15.83)	142,703	0.84	0.87	0.41	32
Year ended 12/31/21	27.42	0.01	6.19	6.20	(0.12)	(2.03)	(2.15)	31.47	22.55	158,060	0.80	0.84	0.03	32
Year ended 12/31/20	23.32	0.09	4.47	4.56	(0.14)	(0.32)	(0.46)	27.42	19.93	119,377	0.80	0.91	0.41	35
Series II														
Year ended 12/31/24	26.30	0.09	3.16	3.25	-	(1.06)	(1.06)	28.49	12.41	756,414	1.12	1.12	0.31	42
Year ended 12/31/23	22.56	0.05	3.92	3.97	(0.23)	-	(0.23)	26.30	17.82	666,053	1.13	1.13	0.19	42
Year ended 12/31/22	30.83	0.04	(5.01)	(4.97)	(0.07)	(3.23)	(3.30)	22.56	(16.04)	562,756	1.09	1.12	0.16	32
Year ended 12/31/21	26.91	(0.07)	6.08	6.01	(0.06)	(2.03)	(2.09)	30.83	22.26	709,699	1.05	1.09	(0.22)	32
Year ended 12/31/20	22.89	0.03	4.39	4.42	(0.08)	(0.32)	(0.40)	26.91	19.63	650,386	1.05	1.16	0.16	35

<sup>(</sup>a) Calculated using average shares outstanding.
(b) Includes adjustments in accordance with accounting principles generally accepted in the United States of America and as such, the net asset value for financial reporting purposes and the returns based upon those net asset values may differ from the net asset value and returns for shareholder transactions. Total returns are not annualized for periods less than one year, if applicable, and do not reflect charges assessed in connection with a variable product, which if included would reduce total returns.

(c) Portfolio turnover is calculated at the fund level and is not annualized for periods less than one year, if applicable.

#### **Notes to Financial Statements**

December 31, 2024

#### NOTE 1-Significant Accounting Policies

Invesco V.I. Main Street Small Cap Fund® (the "Fund") is a series portfolio of AIM Variable Insurance Funds (Invesco Variable Insurance Funds) (the "Trust"). The Trust is a Delaware statutory trust registered under the Investment Company Act of 1940, as amended (the "1940 Act"), as an open-end series management investment company. Information presented in these financial statements pertains only to the Fund. Matters affecting the Fund or each class will be voted on exclusively by the shareholders of the Fund or each class. Current Securities and Exchange Commission ("SEC") guidance, however, requires participating insurance companies offering separate accounts to vote shares proportionally in accordance with the instructions of the contract owners whose investments are funded by shares of each Fund or class

The Fund's investment objective is to seek capital appreciation.

The Fund currently offers two classes of shares, Series I and Series II, both of which are offered to insurance company separate accounts funding variable annuity contracts and variable life insurance policies ("variable products").

The Fund is an investment company and accordingly follows the investment company accounting and reporting guidance in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 946, Financial Services - Investment Companies.

The following is a summary of the significant accounting policies followed by the Fund in the preparation of its financial statements.

#### A. Security Valuations - Securities, including restricted securities, are valued according to the following policy.

A security listed or traded on an exchange is generally valued at its trade price or official closing price that day as of the close of the exchange where the security is principally traded, or lacking any trades or official closing price on a particular day, the security may be valued at the closing bid or ask price on that day. Securities traded in the over-the-counter market are valued based on prices furnished by independent pricing services or market makers. When such securities are valued using prices provided by an independent pricing service they may be considered fair valued. Futures contracts are valued at the daily settlement price set by an exchange on which they are principally traded. Where a final settlement price exists, exchange-traded options are valued at the final settlement price from the exchange where the option principally trades. Where a final settlement price does not exist, exchange-traded options are valued at the mean between the last bid and ask price generally from the exchange where the option principally trades.

Securities of investment companies that are not exchange-traded (e.g., open-end mutual funds) are valued using such company's end-of-business-day net asset value per share.

Deposits, other obligations of U.S. and non-U.S. banks and financial institutions are valued at their daily account value.

Fixed income securities (including convertible debt securities) generally are valued on the basis of prices provided by independent pricing services. Prices provided by the pricing service may be determined without exclusive reliance on quoted prices, and may reflect appropriate factors such as institution-size trading in similar groups of securities, developments related to specific securities, dividend rate (for unlisted equities), yield (for debt obligations), quality, type of issue, coupon rate (for debt obligations), maturity (for debt obligations), individual trading characteristics and other market data. Pricing services generally value debt obligations assuming orderly transactions of institutional round lot size, but a fund may hold or transact in the same securities in smaller, odd lot sizes. Odd lots often trade at lower prices than institutional round lots, and their value may be adjusted accordingly. Debt obligations are subject to interest rate and credit risks. In addition, all debt obligations involve some risk of default with respect to interest and/or principal payments.

Foreign securities' (including foreign exchange contracts) prices are converted into U.S. dollar amounts using the applicable exchange rates as of the close of the New York Stock Exchange ("NYSE"). If market quotations are available and reliable for foreign exchange-traded equity securities, the securities will be valued at the market quotations. Invesco Advisers, Inc. (the "Adviser" or "Invesco") may use various pricing services to obtain market quotations as well as fair value prices. Because trading hours for certain foreign securities end before the close of the NYSE, closing market quotations may become not representative of market value in the Adviser's judgment ("unreliable"). If, between the time trading ends on a particular security and the close of the customary trading session on the NYSE, a significant event occurs that makes the closing price of the security unreliable, the Adviser may fair value the security. If the event is likely to have affected the closing price of the security, the security will be valued at fair value in good faith in accordance with Board- approved policies and related Adviser procedures ("Valuation Procedures"). Adjustments to closing prices to reflect fair value may also be based on a screening process of an independent pricing service to indicate the degree of certainty, based on historical data, that the closing price in the principal market where a foreign security trades is not the current value as of the close of the NYSE. Foreign securities' prices meeting the degree of certainty that the price is not reflective of current value will be priced at the indication of fair value from the independent pricing service. Multiple factors may be considered by the independent pricing service in determining adjustments to reflect fair value and may include information relating to sector indices, American Depositary Receipts and domestic and foreign index futures. Foreign securities may have additional risks including exchange rate changes, potential for sharply devalued currenc

Unlisted securities will be valued using prices provided by independent pricing services or by another method that the Adviser, in its judgment, believes better reflects the security's fair value in accordance with the Valuation Procedures.

Non-traded rights and warrants shall be valued at intrinsic value if the terms of the rights and warrants are available, specifically the subscription or exercise price and the ratio. Intrinsic value is calculated as the daily market closing price of the security to be received less the subscription price, which is then adjusted by the exercise ratio. In the case of warrants, an option pricing model supplied by an independent pricing service may be used based on market data such as volatility, stock price and interest rate from the independent pricing service and strike price and exercise period from verified terms.

Securities for which market prices are not provided by any of the above methods may be valued based upon quotes furnished by independent sources. The mean between the last bid and ask prices may be used to value debt obligations, including corporate loans.

Securities for which market quotations are not readily available are fair valued by the Adviser in accordance with the Valuation Procedures. If a fair value price provided by a pricing service is unreliable, the Adviser will fair value the security using the Valuation Procedures. Issuer specific events, market trends, bid/ask quotes of brokers and information providers and other market data may be reviewed in the course of making a good faith determination of a security's fair value.

The Fund may invest in securities that are subject to interest rate risk, meaning the risk that the prices will generally fall as interest rates rise and, conversely, the prices will generally rise as interest rates fall. Specific securities differ in their sensitivity to changes in interest rates depending on their individual characteristics. Changes in interest rates may result in increased market volatility, which may affect the value and/or liquidity of certain Fund investments.

Valuations change in response to many factors including the historical and prospective earnings of the issuer, the value of the issuer's assets, general market conditions which are not specifically related to the particular issuer, such as real or perceived adverse economic conditions, changes in the general outlook for revenues or corporate earnings, changes in interest or currency rates, regional or global instability, natural or environmental disasters, widespread disease or other public health issues, war, acts of terrorism, significant governmental actions or adverse investor sentiment generally and market liquidity. Because of the inherent uncertainties of valuation, the values reflected in the financial statements may materially differ from the value received upon actual sale of those investments.

The price the Fund could receive upon the sale of any investment may differ from the Adviser's valuation of the investment, particularly for securities that are valued using a fair valuation technique. When fair valuation techniques are applied, the Adviser uses available information, including both observable and unobservable inputs and assumptions, to determine a methodology that will result in a valuation that the Adviser believes approximates market value. Fund

securities that are fair valued may be subject to greater fluctuation in their value from one day to the next than would be the case if market quotations were used. Because of the inherent uncertainties of valuation, and the degree of subjectivity in such decisions, the Fund could realize a greater or lesser than expected gain or loss upon the sale of the investment.

B. Securities Transactions and Investment Income - Securities transactions are accounted for on a trade date basis. Realized gains or losses on sales are computed on the basis of specific identification of the securities sold. Interest income (net of withholding tax, if any) is recorded on an accrual basis from settlement date and includes coupon interest and amortization of premium and accretion of discount on debt securities as applicable. Pay-in-kind interest income and non-cash dividend income received in the form of securities in lieu of cash are recorded at the fair value of the securities received. Dividend income (net of withholding tax, if any) is recorded on the ex-dividend date.

The Fund may periodically participate in litigation related to Fund investments. As such, the Fund may receive proceeds from litigation settlements. Any proceeds received are included in the Statement of Operations as realized gain (loss) for investments no longer held and as unrealized gain (loss) for investments still held

Brokerage commissions and mark ups are considered transaction costs and are recorded as an increase to the cost basis of securities purchased and/or a reduction of proceeds on a sale of securities. Such transaction costs are included in the determination of net realized and unrealized gain (loss) from investment securities reported in the Statement of Operations and the Statement of Changes in Net Assets and the net realized and unrealized gains (losses) on securities per share in the Financial Highlights. Transaction costs are included in the calculation of the Fund's net asset value and, accordingly, they reduce the Fund's total returns. These transaction costs are not considered operating expenses and are not reflected in net investment income reported in the Statement of Operations and the Statement of Changes in Net Assets, or the net investment income per share and the ratios of expenses and net investment income reported in the Financial Highlights, nor are they limited by any expense limitation arrangements between the Fund and the investment adviser.

The Fund allocates income and realized and unrealized capital gains and losses to a class based on the relative net assets of each class.

The Fund recharacterizes distributions received from REIT investments based on information provided by the REIT into the following categories: ordinary income, long-term and short-term capital gains, and return of capital. If information is not available on a timely basis from the REIT, the recharacterization will be based on available information which may include the previous year's allocation. If new or additional information becomes available from the REIT at a later date, a recharacterization will be made in the following year. The Fund records as dividend income the amount recharacterized as ordinary income and as realized gain the amount recharacterized as capital gain in the Statement of Operations, and the amount recharacterized as return of capital as a reduction of the cost of the related investment. These recharacterizations are reflected in the accompanying financial statements.

- Country Determination For the purposes of making investment selection decisions and presentation in the Schedule of Investments, the investment adviser may determine the country in which an issuer is located and/or credit risk exposure based on various factors. These factors include the laws of the country under which the issuer is organized, where the issuer maintains a principal office, the country in which the issuer derives 50% or more of its total revenues, the country that has the primary market for the issuer's securities and its "country of risk" as determined by a third party service provider, as well as other criteria. Among the other criteria that may be evaluated for making this determination are the country in which the issuer maintains 50% or more of its assets, the type of security, financial guarantees and enhancements, the nature of the collateral and the sponsor organization. Country of issuer and/or credit risk exposure has been determined to be the United States of America, unless otherwise noted.
- **D. Distributions** Distributions from net investment income and net realized capital gain, if any, are generally declared and paid to separate accounts of participating insurance companies annually and recorded on the ex-dividend date.
- **E. Federal Income Taxes** The Fund intends to comply with the requirements of Subchapter M of the Internal Revenue Code of 1986, as amended (the "Internal Revenue Code"), necessary to qualify as a regulated investment company and to distribute substantially all of the Fund's taxable earnings to shareholders. As such, the Fund will not be subject to federal income taxes on otherwise taxable income (including net realized capital gain) that is distributed to shareholders. Therefore, no provision for federal income taxes is recorded in the financial statements.

The Fund recognizes the tax benefits of uncertain tax positions only when the position is more likely than not to be sustained. Management has analyzed the Fund's uncertain tax positions and concluded that no liability for unrecognized tax benefits should be recorded related to uncertain tax positions. Management is not aware of any tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will change materially in the next 12 months.

The Fund files tax returns in the U.S. Federal jurisdiction and certain other jurisdictions. Generally, the Fund is subject to examinations by such taxing authorities for up to three years after the filing of the return for the tax period.

- F. Expenses Fees provided for under the Rule 12b-1 plan of a particular class of the Fund and which are directly attributable to that class are charged to the operations of such class. All other expenses are allocated among the classes based on relative net assets.
- **G.** Accounting Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period including estimates and assumptions related to taxation. Actual results could differ from those estimates by a significant amount. In addition, the Fund monitors for material events or transactions that may occur or become known after the period-end date and before the date the financial statements are released to print.
- H. Indemnifications Under the Trust's organizational documents, each Trustee, officer, employee or other agent of the Trust is indemnified against certain liabilities that may arise out of the performance of their duties to the Fund. Additionally, in the normal course of business, the Fund enters into contracts, including the Fund's servicing agreements, that contain a variety of indemnification clauses. The Fund's maximum exposure under these arrangements is unknown as this would involve future claims that may be made against the Fund that have not yet occurred. The risk of material loss as a result of such indemnification claims is considered remote.
- I. Segment Reporting In November 2023, the FASB issued Accounting Standards Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"), with the intent of improving reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses, allowing financial statement users to better understand the components of a segment's profit or loss and assess potential future cash flows for each reportable segment and the entity as a whole thereby enabling better understanding of how an entity's segments impact overall performance. The Fund represents a single operating segment. Subject to the oversight and, when applicable, approval of the Board of Trustees, the Fund's Adviser acts as the Fund's chief operating decision maker ("CODM"), assessing performance and making decisions about resource allocation within the Fund. The CODM monitors the operating results as a whole and the Fund's long-term strategic asset allocation is determined in accordance with the terms of its prospectus based on a defined investment strategy. The financial information provided to and reviewed by the CODM is consistent with that presented in the Fund's financial statements. Adoption of the new standard impacted the Fund's financial statement note disclosures only and did not affect the Fund's financial position or the results of its operations.
- J. Securities Lending The Fund may lend portfolio securities having a market value up to one-third of the Fund's total assets. Such loans are secured by collateral equal to no less than the market value of the loaned securities determined daily by the securities lending provider. Such collateral will be cash or debt securities issued or guaranteed by the U.S. Government or any of its sponsored agencies. Cash collateral received in connection with these loans is invested in short-term money market instruments or affiliated, unregistered investment companies that comply with Rule 2a-7 under the 1940 Act and money market funds (collectively, "affiliated money market funds") and is shown as such on the Schedule of Investments. The Fund bears the risk of loss with respect to the investment of collateral. It is the Fund's policy to obtain additional collateral from or return excess collateral to the borrower by the end of the next business day, following the valuation date of the securities loaned. Therefore, the value of the collateral held may be temporarily less than the value of the securities on loan. When

loaning securities, the Fund retains certain benefits of owning the securities, including the economic equivalent of dividends or interest generated by the security. Lending securities entails a risk of loss to the Fund if, and to the extent that, the market value of the securities loaned were to increase and the borrower did not increase the collateral accordingly, and the borrower failed to return the securities. The securities loaned are subject to termination at the option of the borrower or the Fund. Upon termination, the borrower will return to the Fund the securities loaned and the Fund will return the collateral. Upon the failure of the borrower to return the securities, collateral may be liquidated and the securities may be purchased on the open market to replace the loaned securities. The Fund could experience delays and costs in gaining access to the collateral and the securities may lose value during the delay which could result in potential losses to the Fund. Some of these losses may be indemnified by the lending agent. The Fund bears the risk of any deficiency in the amount of the collateral available for return to the borrower due to any loss on the collateral invested. Dividends received on cash collateral investments for securities lending transactions, which are net of compensation to counterparties, are included in *Dividends from affiliated money market funds* on the Statement of Operations. The aggregate value of securities out on loan, if any, is shown as a footnote on the Statement of Assets and Liabilities.

The Adviser serves as an affiliated securities lending agent for the Fund. The Bank of New York Mellon also serves as a securities lending agent. To the extent the Fund utilizes the Adviser as an affiliated securities lending agent, the Fund conducts its securities lending in accordance with, and in reliance upon, no-action letters issued by the SEC staff that provide guidance on how an affiliate may act as a direct agent lender and receive compensation for those services in a manner consistent with the federal securities laws. For the year ended December 31, 2024, the Fund paid the Adviser \$21,158 in fees for securities lending agent services. Fees paid to the Adviser for securities lending agent services, if any, are included in *Dividends from affiliated money market funds* on the Statement of Operations.

K. Foreign Currency Translations – Foreign currency is valued at the close of the NYSE based on quotations posted by banks and major currency dealers. Portfolio securities and other assets and liabilities denominated in foreign currencies are translated into U.S. dollar amounts at the date of valuation. Purchases and sales of portfolio securities (net of foreign taxes withheld on disposition) and income items denominated in foreign currencies are translated into U.S. dollar amounts on the respective dates of such transactions. The Fund does not separately account for the portion of the results of operations resulting from changes in foreign exchange rates on investments and the fluctuations arising from changes in market prices of securities held. The combined results of changes in foreign exchange rates and the fluctuation of market prices on investments (net of estimated foreign tax withholding) are included with the net realized and unrealized gain or loss from investments in the Statement of Operations. Reported net realized foreign currency gains or losses arise from (1) sales of foreign currencies, (2) currency gains or losses realized between the trade and settlement dates on securities transactions, and (3) the difference between the amounts of dividends, interest, and foreign withholding taxes recorded on the Fund's books and the U.S. dollar equivalent of the amounts actually received or paid. Net unrealized foreign currency gains and losses arise from changes in the fair values of assets and liabilities, other than investments in securities at fiscal period end, resulting from changes in exchange rates.

The Fund may invest in foreign securities, which may be subject to foreign taxes on income, gains on investments or currency repatriation, a portion of which may be recoverable. Foreign taxes, if any, are recorded based on the tax regulations and rates that exist in the foreign markets in which the Fund invests and are shown in the Statement of Operations.

The performance of the Fund may be materially affected positively or negatively by foreign currency strength or weakness relative to the U.S. dollar. Currency rates in foreign countries may fluctuate for a number of reasons, including changes in interest rates, political, economic, or social instability and development, and imposition of currency controls. Currency controls in certain foreign jurisdictions may cause the Fund to experience significant delays in its ability to repatriate its assets in U.S. dollars at quoted spot rates, and it is possible that the Fund's ability to convert certain foreign currencies into U.S. dollars may be limited and may occur at discounts to quoted rates. As a result, the value of the Fund's assets and liabilities denominated in such currencies that would ultimately be realized could differ from those reported on the Statement of Assets and Liabilities. Certain foreign companies may be subject to sanctions, embargoes, or other governmental actions that may limit the ability to invest in, receive, hold, or sell the securities of such companies, all of which affect the market and/or credit risk of the investments. Because of the inherent uncertainties of valuation, the values reflected in the financial statements may materially differ from the value received upon actual sale of those investments.

L. Forward Foreign Currency Contracts – The Fund may engage in foreign currency transactions either on a spot (i.e. for prompt delivery and settlement) basis, or through forward foreign currency contracts, to manage or minimize currency or exchange rate risk.

The Fund may also enter into forward foreign currency contracts for the purchase or sale of a security denominated in a foreign currency in order to "lock in" the U.S. dollar price of that security, or the Fund may also enter into forward foreign currency contracts that do not provide for physical exchange of the two currencies on the settlement date, but instead are settled by a single cash payment calculated as the difference between the agreed upon exchange rate and the spot rate at settlement based upon an agreed upon notional amount (non-deliverable forwards).

A forward foreign currency contract is an obligation between two parties ("Counterparties") to purchase or sell a specific currency for an agreed-upon price at a future date. The use of forward foreign currency contracts for hedging does not eliminate fluctuations in the price of the underlying securities the Fund owns or intends to acquire but establishes a rate of exchange in advance. Fluctuations in the value of these contracts are measured by the difference in the contract date and reporting date exchange rates and are recorded as unrealized appreciation (depreciation) until the contracts are closed. When the contracts are closed, realized gains (losses) are recorded. Realized and unrealized gains (losses) on the contracts are included in the Statement of Operations. The primary risks associated with forward foreign currency contracts include failure of the Counterparty to meet the terms of the contract and the value of the foreign currency changing unfavorably. These risks may be in excess of the amounts reflected in the Statement of Assets and Liabilities.

#### NOTE 2-Advisory Fees and Other Fees Paid to Affiliates

The Trust has entered into a master investment advisory agreement with the Adviser. Under the terms of the investment advisory agreement, the Fund accrues daily and pays monthly an advisory fee to the Adviser based on the annual rate of the Fund's average daily net assets as follows:

Average Daily Net Assets	Rate*
First \$200 million	0.750%
Next \$200 million	0.720%
Next \$200 million	0.690%
Next \$200 million	0.660%
Next \$200 million	0.600%
Next \$4 billion	0.580%
Over \$5 billion	0.560%

The advisory fee paid by the Fund shall be reduced by any amounts paid by the Fund under the administrative services agreement with the Adviser.

For the year ended December 31, 2024, the effective advisory fee rate incurred by the Fund was 0.68%.

Under the terms of a master sub-advisory agreement between the Adviser and each of Invesco Asset Management Deutschland GmbH, Invesco Asset Management Limited, Invesco Asset Management, Inc. and Invesco Canada Ltd. and a separate

sub-advisory agreement with Invesco Capital Management LLC (collectively, the "Affiliated Sub-Advisers") the Adviser, not the Fund, will pay 40% of the fees paid to the Adviser to any such Affiliated Sub-Adviser(s) that provide(s) discretionary investment management services to the Fund based on the percentage of assets allocated to such Affiliated Sub-Adviser(s). Invesco has also entered into a sub-advisory agreement with OppenheimerFunds, Inc. to provide discretionary management services to the Fund.

The Adviser has agreed, for an indefinite period, to waive advisory fees and/or reimburse expenses of all shares to the extent necessary to limit total annual fund operating expenses after fee waiver and/or expense reimbursement (excluding certain items discussed below) of Series I shares to 2.00% and Series II shares to 2.25% of the Fund's average daily net assets (the "boundary limits"). In determining the Adviser's obligation to waive advisory fees and/or reimburse expenses, the following expenses are not taken into account, and could cause the total annual fund operating expenses after fee waiver and/or expense reimbursement to exceed the numbers reflected above: (1) interest; (2) taxes; (3) dividend expense on short sales; (4) extraordinary or non-routine items, including litigation expenses; and (5) expenses that the Fund has incurred but did not actually pay because of an expense offset arrangement. Invesco may amend and/or terminate these boundary limits at any time in its sole discretion and will inform the Board of Trustees of any such changes. The Adviser did not waive fees and/or reimburse expenses during the period under these boundary limits.

Further, the Adviser has contractually agreed, through at least August 31, 2026, to waive the advisory fee payable by the Fund in an amount equal to 100% of the net advisory fees the Adviser receives from the affiliated money market funds on investments by the Fund of uninvested cash (excluding investments of cash collateral from securities lending) in such affiliated money market funds.

For the year ended December 31, 2024, the Adviser waived advisory fees of \$16,970.

The Trust has entered into a master administrative services agreement with Invesco pursuant to which the Fund has agreed to pay Invesco a fee for costs incurred in providing accounting services and fund administrative services to the Fund and to reimburse Invesco for fees paid to insurance companies that have agreed to provide certain administrative services to the Fund. These administrative services provided by the insurance companies may include, among other things: maintenance of master accounts with the Fund; tracking, recording and transmitting net purchase and redemption orders for Fund shares; maintaining and preserving records related to the purchase, redemption and other account activity of variable product owners; distributing copies of Fund documents such as prospectuses, proxy materials and periodic reports, to variable product owners, and responding to inquiries from variable product owners about the Fund. Pursuant to such agreement, for the year ended December 31, 2024, Invesco was paid \$129,837 for accounting and fund administrative services and was reimbursed \$1,355,422 for fees paid to insurance companies. Invesco has entered into a sub-administration agreement whereby State Street Bank and Trust Company ("SSB") serves as fund accountant and provides certain administrative services to the Fund. Pursuant to a custody agreement with the Trust on behalf of the Fund, SSB also serves as the Fund's custodian.

The Trust has entered into a transfer agency and service agreement with Invesco Investment Services, Inc. ("IIS") pursuant to which the Fund has agreed to pay IIS a fee for providing transfer agency and shareholder services to the Fund and reimburse IIS for certain expenses incurred by IIS in the course of providing such services. For the year ended December 31, 2024, expenses incurred under the agreement are shown in the Statement of Operations as *Transfer agent fees*.

The Trust has entered into a master distribution agreement with Invesco Distributors, Inc. ("IDI") to serve as the distributor for the Fund. The Trust has adopted a plan pursuant to Rule 12b-1 under the 1940 Act with respect to the Fund's Series II shares (the "Plan"). The Fund, pursuant to the Plan, pays IDI compensation at the annual rate of 0.25% of the Fund's average daily net assets of Series II shares. The fees are accrued daily and paid monthly. Of the Plan payments, up to 0.25% of the average daily net assets of the Series II shares may be paid to insurance companies who furnish continuing personal shareholder services to customers who purchase and own Series II shares of the Fund. For the year ended December 31, 2024, expenses incurred under the Plan are detailed in the Statement of Operations as Distribution fees.

For the year ended December 31, 2024, the Fund incurred \$28,784 in brokerage commissions with Invesco Capital Markets, Inc., an affiliate of the Adviser and IDI, for portfolio transactions executed on behalf of the Fund.

Certain officers and trustees of the Trust are officers and directors of the Adviser, IIS and/or IDI.

#### NOTE 3-Additional Valuation Information

GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, under current market conditions. GAAP establishes a hierarchy that prioritizes the inputs to valuation methods, giving the highest priority to readily available unadjusted quoted prices in an active market for identical assets (Level 1) and the lowest priority to significant unobservable inputs (Level 3), generally when market prices are not readily available. Based on the valuation inputs, the securities or other investments are tiered into one of three levels. Changes in valuation methods may result in transfers in or out of an investment's assigned level:

- Level 1 Prices are determined using quoted prices in an active market for identical assets.
- Level 2 Prices are determined using other significant observable inputs. Observable inputs are inputs that other market participants may use in pricing a security. These may include quoted prices for similar securities, interest rates, prepayment speeds, credit risk, yield curves, loss severities, default rates, discount rates, volatilities and others. When significant events cause market movements to occur after the close of the relevant foreign securities markets, foreign securities may be fair valued utilizing an independent pricing service.
- Level 3 Prices are determined using significant unobservable inputs. In situations where quoted prices or observable inputs are unavailable (for example, when there is little or no market activity for an investment at the end of the period), unobservable inputs may be used. Unobservable inputs reflect the Adviser's assumptions about the factors market participants would use in determining fair value of the securities or instruments and would be based on the best available information.

The following is a summary of the tiered valuation input levels, as of December 31, 2024. The level assigned to the securities valuations may not be an indication of the risk or liquidity associated with investing in those securities. Because of the inherent uncertainties of valuation, the values reflected in the financial statements may materially differ from the value received upon actual sale of those investments.

	Level 1	Level 2	Level 3	Total
Investments in Securities				
Common Stocks & Other Equity Interests	\$951,414,019	\$ -	\$-	\$ 951,414,019
Money Market Funds	16,618,908	276,888,860	-	293,507,768
Total Investments	\$968,032,927	\$276,888,860	\$-	\$1,244,921,787

#### NOTE 4-Trustees' and Officers' Fees and Benefits

Trustees' and Officers' Fees and Benefits include amounts accrued by the Fund to pay remuneration to certain Trustees and Officers of the Fund. Trustees have the option to defer compensation payable by the Fund, and Trustees' and Officers' Fees and Benefits also include amounts accrued by the Fund to fund such deferred compensation amounts. Those Trustees who defer compensation have the option to select various Invesco Funds in which their deferral accounts shall be deemed to be invested. Finally, certain current Trustees were eligible to participate in a retirement plan that provided for benefits to be paid upon retirement to Trustees over a period of time based on the number of years of service. The Fund may have certain former Trustees who also participate in a retirement plan and receive benefits under

such plan. *Trustees' and Officers' Fees and Benefits* include amounts accrued by the Fund to fund such retirement benefits. Obligations under the deferred compensation and retirement plans represent unsecured claims against the general assets of the Fund.

#### NOTE 5-Cash Balances

The Fund is permitted to temporarily carry a negative or overdrawn balance in its account with SSB, the custodian bank. Such balances, if any at period-end, are shown in the Statement of Assets and Liabilities under the payable caption *Amount due custodian*. To compensate the custodian bank for such overdrafts, the overdrawn Fund may either (1) leave funds as a compensating balance in the account so the custodian bank can be compensated by earning the additional interest; or (2) compensate by paying the custodian bank at a rate agreed upon by the custodian bank and Invesco, not to exceed the contractually agreed upon rate.

#### NOTE 6-Distributions to Shareholders and Tax Components of Net Assets

#### Tax Character of Distributions to Shareholders Paid During the Fiscal Years Ended December 31, 2024 and 2023:

	2024	2023
Ordinary income*	\$ -	\$7,549,573
Long-term capital gain	34,349,419	888
Total distributions	\$34,349,419	\$7,550,461

<sup>\*</sup> Includes short-term capital gain distributions, if any.

#### Tax Components of Net Assets at Period-End:

\$ 11,763,172
102 506 020
102,586,920
241,562,516
68
(72,039)
613,726,811
\$969,567,448

The difference between book-basis and tax-basis unrealized appreciation (depreciation) is due to differences in the timing of recognition of gains and losses on investments for tax and book purposes. The Fund's net unrealized appreciation (depreciation) difference is attributable primarily to wash sales.

The temporary book/tax differences are a result of timing differences between book and tax recognition of income and/or expenses. The Fund's temporary book/tax differences are the result of the trustee deferral of compensation and retirement plan benefits.

Capital loss carryforward is calculated and reported as of a specific date. Results of transactions and other activity after that date may affect the amount of capital loss carryforward actually available for the Fund to utilize. The ability to utilize capital loss carryforward in the future may be limited under the Internal Revenue Code and related regulations based on the results of future transactions.

The Fund does not have a capital loss carryforward as of December 31, 2024.

#### **NOTE 7-Investment Transactions**

The aggregate amount of investment securities (other than short-term securities, U.S. Government obligations and money market funds, if any) purchased and sold by the Fund during the year ended December 31, 2024 was \$397,991,479 and \$377,967,557, respectively. As of December 31, 2024, the aggregate cost of investments, including any derivatives, on a tax basis listed below includes the adjustments for financial reporting purposes as of the most recently completed federal income tax reporting period-end:

#### Unrealized Appreciation (Depreciation) of Investments on a Tax Basis

Aggregate unrealized appreciation of investments	\$269,502,094
Aggregate unrealized (depreciation) of investments	(27,939,578)
Net unrealized appreciation of investments	\$241,562,516

Cost of investments for tax purposes is \$1,003,359,271.

#### NOTE 8-Reclassification of Permanent Differences

Primarily as a result of differing book/tax treatment of ordinary income, partnerships and net operating losses, on December 31, 2024, undistributed net investment income was increased by \$2,979, undistributed net realized gain was decreased by \$817,187 and shares of beneficial interest was increased by \$814,208. This reclassification had no effect on the net assets of the Fund.

#### NOTE 9-Share Information

		Summary of Share Activity			
		Year ended December 31, 2024 <sup>(a)</sup>		Year ended December 31, 2023	
	Shares	Amount	Shares	Amount	
Sold:					
Series I	1,570,250	\$ 45,007,834	1,153,496	\$ 28,424,788	
Series II	4,097,751	115,174,331	3,777,631	89,873,092	

#### Summary of Share Activity

		Year ended December 31, 2024 <sup>(a)</sup>		r ended er 31, 2023
	Shares	Amount	Shares	Amount
Issued as reinvestment of dividends:				
Series I	254,324	\$ 7,337,261	84,344	\$ 1,849,665
Series II	960,603	27,012,156	265,895	5,700,796
Reacquired:				
Series I	(1,011,610)	(29,000,154)	(947,179)	(23,467,056)
Series II	(3,836,222)	(106,922,893)	(3,666,178)	(87,148,825)
Net increase in share activity	2,035,096	\$ 58,608,535	668,009	\$ 15,232,460

<sup>(</sup>a) There are entities that are record owners of more than 5% of the outstanding shares of the Fund and in the aggregate own 52% of the outstanding shares of the Fund. The Fund and the Fund's principal underwriter or adviser, are parties to participation agreements with these entities whereby these entities sell units of interest in separate accounts funding variable products that are invested in the Fund. The Fund, Invesco and/or Invesco affiliates may make payments to these entities, which are considered to be related to the Fund, for providing services to the Fund, Invesco and/or Invesco affiliates including but not limited to services such as, securities brokerage, third party record keeping and account servicing and administrative services. The Fund has no knowledge as to whether all or any portion of the shares owned of record by these entities are also owned beneficially.

## Report of Independent Registered Public Accounting Firm

To the Board of Trustees of AIM Variable Insurance Funds (Invesco Variable Insurance Funds) and Shareholders of Invesco V.I. Main Street Small Cap Fund®

#### **Opinion on the Financial Statements**

We have audited the accompanying statement of assets and liabilities, including the schedule of investments, of Invesco V.I. Main Street Small Cap Fund® (one of the funds constituting AIM Variable Insurance Funds (Invesco Variable Insurance Funds), referred to hereafter as the "Fund") as of December 31, 2024, the related statement of operations for the year ended December 31, 2024, the statement of changes in net assets for each of the two years in the period ended December 31, 2024, including the related notes, and the financial highlights for each of the five years in the period ended December 31, 2024 (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Fund as of December 31, 2024, the results of its operations for the year then ended, the changes in its net assets for each of the two years in the period ended December 31, 2024 and the financial highlights for each of the five years in the period ended December 31, 2024 in conformity with accounting principles generally accepted in the United States of America.

#### **Basis for Opinion**

These financial statements are the responsibility of the Fund's management. Our responsibility is to express an opinion on the Fund's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Fund in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits of these financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. Our procedures included confirmation of securities owned as of December 31, 2024 by correspondence with the custodian, transfer agent and brokers. We believe that our audits provide a reasonable basis for our opinion.

/s/PricewaterhouseCoopers LLP

Houston, Texas February 14, 2025

We have served as the auditor of one or more of the investment companies in the Invesco group of investment companies since at least 1995. We have not been able to determine the specific year we began serving as auditor.

### **Tax Information**

Form 1099-DIV, Form 1042-S and other year-end tax information provide shareholders with actual calendar year amounts that should be included in their tax returns. Shareholders should consult their tax advisers.

The following distribution information is being provided as required by the Internal Revenue Code or to meet a specific state's requirement.

The Fund designates the following amounts or, if subsequently determined to be different, the maximum amount allowable for its fiscal year ended December 31, 2024:

#### Federal and State Income Tax

Long-Term Capital Gain Distributions	\$34.349.419
Qualified Dividend Income*	0.00%
Corporate Dividends Received Deduction*	0.00%
U.S. Treasury Obligations*	0.00%
Qualified Business Income*	0.00%
Business Interest Income*	0.00%

<sup>\*</sup> The above percentages are based on ordinary income dividends paid to shareholders during the Fund's fiscal year.

## Other Information Required in Form N-CSR (Items 8-11)

<u>Changes in and Disagreements with Accountants for Open-End Management Investment Companies</u>
Not applicable.

**Proxy Disclosures for Open-End Management Investment Companies** 

Not applicable.

Remuneration Paid to Directors, Officers, and Others of Open-End Management Investment Companies

The aggregate remuneration paid to directors, officers and others is disclosed within the financial statements.

Statement Regarding Basis for Approval of Investment Advisory Contracts

Not applicable.